Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastrointestinal Cancer

The goal of this clinical trial is to learn the safety of tumor neoantigen vaccine combined with neoantigen vaccine induced T-cell in treating advanced gastrointestinal cancer in adults. It will also learn if the combined treatment works to treat advanced gastrointestinal cancer.The main questions it aims to answer are:What medical problems do participants have when using the combined treatment? Does tumor neoantigen vaccine combined with neoantigen vaccine induced T-cell eliminate or shrink the tumor, and can it prolong the patient's survival period?

NCT Number	NCT07329894
Lead Sponsor	Beijing GoBroad Hospital Collaborators: NeoCura
Conditions	Gastrointestinal Cancer
Enrollment	18 participants
Start Date	2026-02
Primary Completion	2027-08 (estimated)
Study Completion	2029-10 (estimated)
Updated on ClinicalTrials.gov	2026-02-12